The natural and synthetic compounds presented here as HR HPV E6 protein inhibitors by either target E6/E6AP complex or the E6/E6AP/p53 complex formation are a valid starting point for drug design and development in cervical cancer management. This evidence concerns the gene UBE3A and cervical cancer.